Select Language:
A recent study suggests that metformin, a commonly used medication for type 2 diabetes, may mimic some of the effects of exercise in the body, particularly in men undergoing treatment for prostate cancer. Published in EMBO Molecular Medicine, the research sheds light on how the body manages energy and weight during cancer therapy, especially when patients are unable to stay physically active.
Exercise is well recognized for its numerous health benefits, including weight regulation, improved blood sugar control, heart health support, and enhanced overall wellbeing. For cancer patients, it can also help alleviate treatment side effects and speed recovery. However, many patients struggle to maintain a regular exercise routine due to side effects such as fatigue, weakness, and discomfort caused by treatments like hormone therapy.
This challenge has led scientists to ponder whether the biological processes triggered by exercise could be activated through other means. To explore this, researchers from the University of Miami Miller School of Medicine focused on metformin. They investigated a molecule called N-lactoyl-phenylalanine, or Lac-Phe, which is produced during intense physical activity when lactate—accumulating during exercise—combines with phenylalanine, a protein building block.
Previous studies linked Lac-Phe to reduced appetite and better weight management, mirroring some effects of regular exercise. The new research revealed that metformin can increase Lac-Phe levels in prostate cancer patients even when they are not exercising. This suggests that metformin might activate similar pathways used by physical activity, offering metabolic benefits for those unable to exercise.
The study concentrated on men undergoing hormone therapy for prostate cancer, which often disrupts metabolism and leads to weight gain, insulin resistance, and a higher risk of heart disease. Maintaining metabolic health during such treatment is crucial for both immediate wellbeing and long-term health outcomes. Results showed that Lac-Phe levels in patients taking metformin increased to levels comparable to those seen after intense exercise, despite the patients being sedentary at the time. This effect persisted even after hormone therapy started.
However, the study also found no direct link between elevated Lac-Phe levels and a reduction in tumor growth, indicating that while metformin may support metabolic health, it doesn’t directly impact cancer progression through this pathway. Additionally, metformin influences other bodily pathways; for example, it raised levels of GDF-15, a hormone associated with appetite regulation and weight loss. Yet, Lac-Phe was more closely tied to actual changes in body weight.
These findings offer valuable insights into how treatments affect the body and how existing drugs might be repurposed to improve overall health in cancer patients. They emphasize focusing not just on the disease itself but also on improving quality of life and bodily function during treatment.
It’s important to note that metformin isn’t a substitute for exercise, which provides benefits beyond what medication can offer. More extensive research is needed to validate these findings across larger and more diverse populations.
Overall, this study highlights a significant advance: a well-known, accessible drug like metformin may help support metabolic health in patients unable to engage in physical activity, potentially improving their comfort and resilience during cancer treatment.
ChatGPT
Perplexity
Gemini AI
Grok AI
